Deals in brief
Tetraphase Pharmaceuticals to merge with AcelRx
BioNTech acquires T cell therapy-focused Neon for $67m
BioNTech has acquired Neon Therapeutics in an all stock transaction valued at $2.18 per share or approximately $67m.
According to the terms of the deal, Neon will be merged with ENDOR Lights, a wholly owned subsidiary of BioNTech.
Applied DNA, Takis Biotech design four Covid-19 vaccine candidates
Orionis and Novartis enter drug discovery deal
Life sciences firm Orionis Biosciences has partnered with Novartis to discover and design new drugs for the treatment of a variety of diseases.
Orionis portfolio includes technologies for genome-scale drug discovery and molecular design of therapeutic modalities, intended to address the most challenging protein targets.
The four-year alliance with Novartis will leverage Orionis’ Allo-Glue technology platform to identify and design small molecule drugs, including protein degraders.
According to Orionis, the deal involves research funding, a convertible note investment, royalties and also clinical milestones.
Vir Biotechnology partners NIH and Biogen on coronavirus antibodies
BioNTech signs Covid-19 vaccine deals with Pfizer and Fosun
Iktos and SRI to use AI for Covid-19 drug development
Artificial intelligence (AI) technology provider Iktos and research centre SRI International have partnered to discover and develop drugs to treat various viruses, including the novel coronavirus that causes Covid-19 and influenza.
Iktos will combine its generative modelling technology with SRI’s fully automated synthetic chemistry platform called SynFini to design compounds and speed-up the identification of drug candidates.